The widespread adoption of glucagon-like peptide-1 (GLP‑1) weight-loss medications has introduced significant complexities for life insurance and reinsurance firms in assessing mortality risk. Recent research from Munich Re indicates that approved drugs such as semaglutide and tirzepatide could substantially reduce overall mortality among users. However, uncertainty over patients’ adherence and consistency in taking these medications […]